STOCK TITAN

Healthy Extracts Expects Q1 2022 Net Revenue up 187% to Record $489,000, Driving First Profitable Quarter

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Healthy Extracts Inc. (OTCQB: HYEX) reported preliminary Q1 results for 2022, estimating net revenue over $489,000, a 187% increase year-over-year. This growth is attributed to direct-to-consumer channel expansion and a four-fold rise in subscription revenue. The company anticipates its first positive net income quarter, maintaining its 2022 forecast of over $3 million in revenue. Healthy Extracts has focused on building a foundation in the brain and heart health markets through acquisitions and clinical studies, aiming for 100% sales growth this year.

Positive
  • Net revenue estimate of over $489,000, up 187% year-over-year.
  • Strong growth expected to lead to the first positive net income quarter.
  • Plans to double full-year revenue to over $3 million.
  • Expansion of direct-to-consumer channels, including a four-fold increase in subscription revenue.
  • Progress in the brain and heart health supplement market through acquisitions and clinical studies.
Negative
  • None.

LAS VEGAS, April 12, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported preliminary unaudited results for the first quarter ended March 31, 2022.

Net revenue for the first quarter is expected to total more than $489,000, up 187% over the same year-ago quarter, and keeps full year outlook on track for revenue to double to more than $3 million.

“Our record top-line for a first quarter resulted primarily from expansion of direct-to-consumer channels, including a four-fold increase in recurring revenue from product subscriptions,” stated Duke Pitts, president of Healthy Extracts. “We also expect this strong performance to drive our first-ever positive net income quarter.”

Over the past year, the company established a solid foundation for addressing the fast-growing brain and heart health supplement market, including key acquisitions and successful clinical studies that support its products’ health benefit claims.

“We believe the progress we have made, particularly with expanding our sales channels and portfolio of clinically proven natural products, keeps us on course for our earlier guided 100% sales growth in 2022,” added Duke. “Together with our continued focus on building our recurring revenue stream from subscriptions, we anticipate a continued strengthening of our shareholder value throughout the year.”
  
The preliminary unaudited results are estimates only and are subject to revision until the company reports its financial results for the first quarter ended March 31, 2022, which it expects to report in May.

About Healthy Extracts “Live Life Young Again”
Healthy Extracts Inc. is a platform for developing or acquiring science-forward, clinically proven, plant-based proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market.

The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruit™. This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids, and with healthy heart benefits backed by more than 17 clinical studies.

UBN KETONOMICS® proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio of multiple issued and pending patents.
  
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.

Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2022, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Food and Drug Administration Disclosure

The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™

Healthy Extracts Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact

Investor Contact:
Ronald Both or Justin Lumley
CMA
Tel (949) 432-7566
Email contact

Media Contact:
Tim Randall
CMA
Tel (949) 432-7572
Email contact


FAQ

What were Healthy Extracts' Q1 2022 revenue results?

Healthy Extracts Inc. reported preliminary Q1 2022 revenue estimates over $489,000, representing a 187% increase from the previous year.

What factors contributed to Healthy Extracts' revenue growth in Q1 2022?

The revenue growth was primarily driven by the expansion of direct-to-consumer channels and a significant increase in subscription revenue.

What is Healthy Extracts' revenue projection for the full year 2022?

Healthy Extracts expects to double its full-year revenue to over $3 million.

When will Healthy Extracts report its financial results for Q1 2022?

Healthy Extracts plans to report its financial results for Q1 2022 in May.

What are Healthy Extracts' expectations for net income in Q1 2022?

The company anticipates its first-ever positive net income quarter in Q1 2022.

HEALTHY EXTRACTS INC

OTC:HYEX

HYEX Rankings

HYEX Latest News

HYEX Stock Data

9.73M
1.09M
72.84%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Henderson